NCT06339255 Italian Observational Study on CAR-T Therapy for Lymphoma
| NCT ID | NCT06339255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Paolo Corradini |
| Condition | Diffuse Low Grade B-Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,300 participants |
| Start Date | 2019-10-30 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,300 participants in total. It began in 2019-10-30 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.
Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of DLCBL, PMBCL, MCL and FL eligible for CAR-T treatment with commercialy available products in Italy. Exclusion Criteria: * Not applicable
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06339255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diffuse Low Grade B-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06339255 currently recruiting?
Yes, NCT06339255 is actively recruiting participants. Contact the research team at paolo.corradini@istitutotumori.mi.it for enrollment information.
Where is the NCT06339255 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06339255 clinical trial?
NCT06339255 is sponsored by Paolo Corradini. The trial plans to enroll 5,300 participants.